Author: Spotrate Publisher

Oncolytics says nearly all planned REO 033 sites are active and expects a Part A interim update by year-end. We examine its earlier REO 022 signal and the distinct oncology exposure of Roche and Novartis.

Fuse Oncology plans to add physicists, dosimetrists, therapists and nurses to its FuseRx workflow, building on its physician-focused launch and a University of Michigan planning tool. The company will demonstrate the expanded roles at ASTRO 2026.

iA Financial shares have moved above a widely followed 200-day moving average, putting technical momentum in focus. Spotrate examines what the signal says—and does not say—alongside the company’s broader corporate story.

Akeso heads toward ESMO 2026 with nearly 30 bispecific-antibody studies, expanding commercial sales and multiple Phase III readouts. The next test is whether clinical momentum can translate into broader regulatory and commercial execution.

Fortuna Mining’s Q2 2026 results showed strong cash generation and a 63% adjusted EBITDA margin, while management expects costs to ease in the second half. Spotrate compares Fortuna with Agnico Eagle, Kinross and B2Gold across production, AISC, earnings and free cash flow.